Abstract:Abstract Homologous recombination (HR) repair deficiency impairs the proper maintenance of genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1). Inhibitors of nuclear PARPs are effective therapeutics for a number of different types of cancers. Here we review key concepts and current progress on the therapeutic use of PARP inhibitors (PARPi). PARPi selectively induce synthetic lethality in cancer cells with homologous recombination deficiencies (HRDs), the most notable being cancer cells harboring mutations in the BRCA1 and BRCA2 genes. Recent clinical evidence, however, shows that PARPi can be effective as cancer therapeutics regardless of BRCA1/2 or HRD status, suggesting that a broader population of patients might benefit from PARPi therapy. Currently, four PARPi have been approved by the Food and Drug Administration (FDA) for the treatment of advanced ovarian and breast cancer with deleterious BRCA mutations. Although PARPi have been shown to improve progression-free survival, cancer cells inevitably develop resistance, which poses a significant obstacle to the prolonged use of PARP inhibitors. For example, somatic BRCA1/2 reversion mutations are often identified in patients with BRCA1/2 -mutated cancers after treatment with platinum-based therapy, causing restoration of HR capacity and thus conferring PARPi resistance. Accordingly, PARPi have been studied in combination with other targeted therapies to overcome PARPi resistance, enhance PARPi efficacy, and sensitize tumors to PARP inhibition. Moreover, multiple clinical trials are now actively underway to evaluate novel combinations of PARPi with other anticancer therapies for the treatment of PARPi-resistant cancer. In this review, we highlight the mechanisms of action of PARP inhibitors with or without BRCA1/2 defects and provide an overview of the ongoing clinical trials of PARPi. We also review the current progress on PARPi-based combination strategies and PARP inhibitor resistance.

PARP inhibitor resistance: the underlying mechanisms and clinical implications

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Molecular mechanism of PARP inhibitor resistance

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.

Mechanism of PARP inhibitor resistance and potential overcoming strategies

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Advances and Perspectives of PARP Inhibitors

BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality

Facing Inevitable PARPis Resistance: Mechanisms and Therapeutic Strategies for Breast Cancer Treatment

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer

Combating Tumor PARP Inhibitor Resistance: Combination Treatments, Nanotechnology, and Other Potential Strategies

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

Recent Advancements In Parp Inhibitors-Based Targeted Cancer Therapy

Mechanism of Action of PARP Inhibitors

Understanding and overcoming resistance to PARP inhibitors in cancer therapy

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies

Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer

Emerging Strategies to Overcome PARP Inhibitors' Resistance in Ovarian Cancer